MolMed completes enrolment in pivotal Phase III trial of
NGR-hTNF in relapsed mesothelioma patients
Milan (Italy), 13 December 2012 – MolMed S.
p.
A.
(MLM.
MI) announces
completion of enrolment in the pivotal NGR015 Phase III trial of its
investigational...
More
MolMed completes enrolment in pivotal Phase III trial of
NGR-hTNF in relapsed mesothelioma patients
Milan (Italy), 13 December 2012 – MolMed S.
p.
A.
(MLM.
MI) announces
completion of enrolment in the pivotal NGR015 Phase III trial of its
investigational drug NGR-hTNF in relapsed malignant pleural mesothelioma, a
poor-prognosis disease linked to asbestos exposure with increasing incidence
worldwide.
Primary efficacy results are expected in the third quarter of 2013.
NGR-hTNF, a novel vascular targeting agent, could represent a new treatment
option to potentially extend the lives of patients with relapsed mesothelioma
- an indication without specific regulatory-approved therapies.
Both the
European Medicines Agency (EMA) and the U.
S.
Food and Drug Administration
(FDA) granted NGR-hTNF Orphan Drug designation for this indication.
Claudio Bordignon, MolMed’s Chairman and CEO, comments: “We are very
proud that the accrual completion in this 390-patient trial was achieved earlier
tha
Less
